Table 1.
Sociodemographic, clinical and biomarkers measures divided by MCI sub-type at baseline.
| SAMPLE |
Total |
aMCI |
NaMCI |
md aMCI |
md naMCI |
p-value |
|
|---|---|---|---|---|---|---|---|
| N | 80 | 31 | 8 | 35 | 6 | – | |
| Gender | M/F | 37/43 | 17/14 | 5/3 | 13/22 | 2/4 | ns |
| Age (years) | Mean | 70.03 | 70.39 | 73.05 | 69.81 | 65.33 | ns |
| SD | 7.29 | 6.29 | 8.92 | 7.08 | 10.61 | ||
| Education (years) | Mean | 9.69 | 10.50 | 9.75 | 9.44 | 6.67 | ns |
| SD | 3.84 | 4.13 | 4.68 | 3.40 | 2.16 | ||
| MMSE | Mean | 25.60 | 25.93 | 25.79 | 25.18 | 26.03 | ns |
| SD | 2.73 | 2.81 | 3.16 | 2.62 | 2.66 | ||
| Aβ42 < 500 (ng/l) | Mean | 562.76 | 609.81 | 498.38 | 510.74 | 701.09 | ns |
| SD | 289.39 | 333.97 | 317.16 | 225.76 | 313.63 | ||
| t-Tau > 450 (ng/l) | Mean | 488.40 | 534.84 | 546.39 | 460.31 | 332.63 | ns |
| SD | 375.10 | 414.30 | 193.56 | 394.39 | 152.06 | ||
| p-Tau > 61 (ng/l) | Mean | 70.77 | 78.07 | 94.18 | 61.61 | 52.50 | ns |
| SD | 35.69 | 36.23 | 39.55 | 32.79 | 22.49 | ||
| t-Tau/Aβ42 | Mean | 1.16 | 1.26 | 1.41 | 1.12 | 0.54 | ns |
| SD | 1.07 | 1.19 | 0.77 | 1.08 | 0.34 | ||
| p-Tau/Aβ42 | Mean | 0.17 | 0.19 | 0.26 | 0.14 | 0.09 | ns |
| SD | 0.13 | 0.15 | 0.17 | 0.11 | 0.04 | ||
| FDG SPM AD | n | 43 | 14 | 5 | 22 | 2 | ns |
| FDG SPM FTD | n | 17 | 9 | 2 | 5 | 1 | ns |
| FDG SPM DLB | n | 1 | 0 | 0 | 1 | 0 | ns |
| FDG SPM negative | n | 19 | 8 | 1 | 7 | 3 | ns |
Abbreviations: MCI = mild cognitive impairment, aMCI = amnestic (single-domain) MCI, md aMCI = multi-domain amnestic MCI, naMCI = non-amnestic (single-domain) MCI, md naMCI = multi-domain non-amnestic MCI, SD = standard deviation, AD = Alzheimer's disease, FTD = frontotemporal lobar degeneration, DLB = dementia with Lewy bodies, n = number. Statistical differences were assessed performing ANOVA and Chi-square analyses.